-
Product Insights
NewHospital Acquired Pneumonia (HAP) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Hospital Acquired Pneumonia (HAP) - Global Clinical Trials Review, 2024" provides an overview of Hospital Acquired Pneumonia (HAP) Clinical trials scenario. This report provides top line data relating to the clinical trials on Hospital Acquired Pneumonia (HAP). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
NewBronchiectasis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Bronchiectasis Clinical Trial Report Overview A total of 394 Bronchiectasis clinical trials were conducted as of March 2024. The Bronchiectasis clinical trial report provides a comprehensive understanding of the Bronchiectasis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe ·       North America ·       ...
-
Product Insights
Idiopathic Pulmonary Fibrosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Idiopathic Pulmonary Fibrosis Clinical Trial Report Overview A total of 713 idiopathic pulmonary fibrosis clinical trials were conducted as of January 2024. The Idiopathic Pulmonary Fibrosis clinical trial report provides a comprehensive understanding of the idiopathic pulmonary fibrosis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions...
-
Product Insights
Allergic Rhinitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Allergic Rhinitis - Drugs In Development, 2023’, provides an overview of the Allergic Rhinitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Allergic Asthma – Drugs In Development, 2023
Global Markets Direct’s, ‘Allergic Asthma - Drugs In Development, 2023’, provides an overview of the Allergic Asthma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Hospital Acquired Pneumonia (HAP) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hospital Acquired Pneumonia (HAP) - Drugs In Development, 2023’, provides an overview of the Hospital Acquired Pneumonia (HAP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) - Drugs In Development, 2023’, provides an overview of the Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Ventilator Associated Pneumonia (VAP) – Drugs In Development, 2023
Global Markets Direct’s, ‘Ventilator Associated Pneumonia (VAP) - Drugs In Development, 2023’, provides an overview of the Ventilator Associated Pneumonia (VAP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Acute Lung Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Lung Injury - Drugs In Development, 2023’, provides an overview of the Acute Lung Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Lung Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Respiratory Distress Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Respiratory Distress Syndrome - Drugs In Development, 2023’, provides an overview of the Respiratory Distress Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...